Metraipolis › archive › dc_dbf32c530fcb
Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41462859
- DOI
- 10.3390/biomedicines13122844
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T09:03:18.352Z
- SHA-256 of the archived text
30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b- Stable URL of this page
https://metraipolis.com/documento/dc_dbf32c530fcb
How to cite
Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859 — Europe PMC (en), https://europepmc.org/article/MED/41462859 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dbf32c530fcb (Metraipolis archive dc_dbf32c530fcb, sha256 30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b)
BibTeX
@misc{dcdbf32c530fcb,
title = {Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience — Europe PMC PMID:41462859},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41462859},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dbf32c530fcb; sha256 30d96db71e747cb8117b2636761e2bbce2bc8ffa2e9252ec944f60d4c543709b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41462859. Agents can read the archived copy with the MCP tool read_document.